Discuss current and emerging bispecifics for hematologic malignancies and solid tumors with SITC's #virtual Advances in Cancer Immunotherapy™: A Focus on Bispecifics and T Cell Engagers program Feb. 25.

Register now: https://www.sitcancer.org/edu/aci/bispecifics-engagers
#LearnACI

Gain in-depth education on all aspects of clinical implementation of IO for skin cancers! Learn from leading experts and advance your education with SITC's #virtual ACI: A Focus on Skin Cancers program Oct. 3. View topics: https://www.sitcancer.org/edu/aci/skin-cancers 🧪 #LearnACI #MedSky #OncSky

Gain in-depth education on all aspects of clinical implementation of IO for skin cancers! Learn from leading experts and advance your education with SITC's #virtual ACI: A Focus on Skin Cancers program Oct. 3. View topics: www.sitcancer.org/edu/aci/skin... 🧪

#LearnACI #MedSky #OncSky

Explore emerging perspectives on toxicities following CAR T and bispecific therapies. Learn from a panel of experts with SITC’s #virtual ACI: A Focus on Hematologic Malignancies program Aug. 25.

Learn more & register: www.sitcancer.org/edu/aci/hema...

#LearnACI

Receive updates on the latest studies and approvals of IO for melanoma and non-melanoma skin cancers! Join us Oct. 3 for a live virtual cancer #immunotherapy program, ACI: A Focus on Skin Cancers.

Register now: www.sitcancer.org/edu/aci/skin...

#LearnACI

View emerging data from ongoing trials of new IO-based approaches to treat hematologic malignancies! Access the most recent cancer IO updates at SITC's #virtual ACI: A Focus on Hematologic Malignancies program Aug. 25. View topics: https://www.sitcancer.org/edu/aci/hematologic-malignancies #LearnACI #MedSky #Immuno 🧪

View emerging data from ongoing trials of new IO-based approaches to treat hematologic malignancies! Access the most recent cancer IO updates at SITC's #virtual ACI: A Focus on Hematologic Malignancies program Aug. 25.

View topics: www.sitcancer.org/edu/aci/hema...

#LearnACI #MedSky #Immuno 🧪

Screenshots of irAE resources

screenshot of resources for caregivers

📣 irAE education and resources are out there!! Marianne Davies @yalemedicine.bsky.social and Lisa Kottschade @mayocliniccancer.bsky.social #LearnACI @sitcancer.bsky.social @ascocancer.bsky.social

Loved this session! Big thanks to Alexa Meara @ohiostatemed.bsky.social for breaking it all down and sharing so many great insights on irAEs!

#LearnACI #CanSky

Which cytokine do we need to target: Alexa Meara @ohiostatemed.bsky.social is your girl if you love learning more about the biology behind clinical manifestations of irAE and the potential drugs we could use to treat them rationally #LearnACI @sitcancer.bsky.social

Love this take on steroids and irAE - we had to build the plane as we flew: we quickly found they worked, we needed high doses to keep people from dying, but what really are the data behind optimal dosing tapers? (Hint we need more data) Jordan McPherson @utah.edu #learnACI @sitcancer.bsky.social

IO trends affect irAE care: subcut IO reduces contact time ( logistic benefits for pts but also potential to miss early recognition of irAE) and increasing use of IO in earlier stages (likely differences in irAE spectrum) -Matt Hadfield @brownmedicine.bsky.social #learnACI @sitcancer.bsky.social

📚🎙️Come discuss updates and the future of IO use in #MBC with me on Feb 28th!

A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social

#Immunotherapy for women’s malignancies continue to evolve. #SITC’s ACI: A Focus on Women’s Malignancies program provides clinicians with current updates in the use of IO to treat early/late-stage breast cancer. Join Feb. 28.

Register: www.sitcancer.org/education/ac...

#LearnACI #breastcancer